Keynote 355 plus#

We hope these biomarkers could help to identify suitable patients and realize precision immunotherapy.ДЄmong women, breast cancer (BC) is the malignant tumor with the highest morbidity and the second highest mortality ( 1вЂ“ 4). Here, we select some biomarkers related to ICIs and discuss their potential predictive and prognostic value in TNBC.

TILs also have potential predictive value in TNBC. Other studies have shown that advanced TNBC patients with TMB в‰Ґ10 mutations/Mb can achieve clinical benefits from pembrolizumab. These inconsistent conclusions suggest that PD-L1 is the best to date but an imperfect predictive biomarker for efficacy of ICIs. However, in patients with early TNBC receiving neoadjuvant therapy, PD-L1 cannot predict the efficacy of ICIs.

Keynote 355 plus#

Clinical trials have shown that PD-L1-positive patients with advanced TNBC benefit from ICIs plus chemotherapy. Recently, various biomarkers have been extensively explored, such as PD-L1, TILs and tumor mutational burden (TMB).

Therefore, it is important to identify biomarkers that can predict the efficacy of IC inhibitors (ICIs) in TNBC. However, previous studies have shown that monotherapy has little efficacy and only some TNBC patients can benefit from immunotherapy. TNBC has more tumor-infiltrating lymphocytes (TILs) and higher rate of mutation and programmed cell death ligand-1 (PD-L1) expression than other subtypes of breast cancer have.

In recent years, immunotherapy based on immune checkpoint (IC) inhibition has emerged as a promising therapeutic strategy in TNBC. Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaДЄs an aggressive subtype of breast cancer, triple-negative breast cancer (TNBC) is associated with poor prognosis and lack of effective therapy, except chemotherapy.Qiaorui Tan вЂ , Sha Yin вЂ , Dongdong Zhou, Yajing Chi, Xiaochu Man and Huihui Li *